Occudo Quantitative Strategies LP Acquires 10,268 Shares of Paysign, Inc. (NASDAQ:PAYS)

Occudo Quantitative Strategies LP boosted its holdings in shares of Paysign, Inc. (NASDAQ:PAYS) by 56.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 28,429 shares of the company’s stock after purchasing an additional 10,268 shares during the quarter. Occudo Quantitative Strategies LP’s holdings in Paysign were worth $86,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. PDT Partners LLC acquired a new position in shares of Paysign in the fourth quarter valued at $39,000. Wells Fargo & Company MN raised its stake in shares of Paysign by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 15,385 shares of the company’s stock valued at $46,000 after purchasing an additional 5,243 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of Paysign by 33.5% in the fourth quarter. SG Americas Securities LLC now owns 15,508 shares of the company’s stock valued at $47,000 after purchasing an additional 3,895 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Paysign in the fourth quarter valued at $78,000. Finally, Bard Associates Inc. raised its stake in shares of Paysign by 19.7% in the fourth quarter. Bard Associates Inc. now owns 33,450 shares of the company’s stock valued at $101,000 after purchasing an additional 5,497 shares in the last quarter. Institutional investors own 25.89% of the company’s stock.

Paysign Price Performance

Shares of NASDAQ:PAYS opened at $3.61 on Monday. The business’s fifty day moving average price is $2.36 and its two-hundred day moving average price is $2.81. Paysign, Inc. has a fifty-two week low of $1.80 and a fifty-two week high of $5.59. The stock has a market capitalization of $195.73 million, a price-to-earnings ratio of 24.07 and a beta of 0.23.

Paysign (NASDAQ:PAYS) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.01. Paysign had a return on equity of 30.64% and a net margin of 14.28%. The firm had revenue of $18.60 million for the quarter, compared to analysts’ expectations of $17.49 million. Research analysts expect that Paysign, Inc. will post 0.21 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently commented on PAYS. Lake Street Capital upped their target price on Paysign from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Friday, May 9th. LADENBURG THALM/SH SH upped their target price on Paysign from $7.25 to $8.25 and gave the company a “buy” rating in a research note on Friday, May 9th. Barrington Research restated an “outperform” rating and issued a $7.00 target price on shares of Paysign in a research note on Wednesday, March 26th. Finally, DA Davidson upped their target price on Paysign from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Wednesday, May 14th.

Insider Buying and Selling at Paysign

In other Paysign news, CEO Mark Newcomer sold 100,000 shares of the company’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $2.73, for a total value of $273,000.00. Following the sale, the chief executive officer now directly owns 8,936,886 shares in the company, valued at $24,397,698.78. This represents a 1.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 22.40% of the company’s stock.

About Paysign

Paysign, Inc provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card.